ProfileGDS5678 / 1458483_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 36% 37% 37% 38% 37% 37% 35% 37% 37% 36% 37% 38% 37% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8608236
GSM967853U87-EV human glioblastoma xenograft - Control 22.84937
GSM967854U87-EV human glioblastoma xenograft - Control 32.8510737
GSM967855U87-EV human glioblastoma xenograft - Control 42.8039638
GSM967856U87-EV human glioblastoma xenograft - Control 52.7974437
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9290537
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8438935
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8313537
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8279237
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8152436
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8333237
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8302238
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8477737
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8377637